BRIEF-Living Cell Technologies Secures Funding For Third Clinical Trial Of NTCELL In Parkinson's Disease
BRIEF-Living Cell Technologies Secures Funding For Third Clinical Trial Of NTCELL In Parkinson's Disease
Brief-Living Cell Technologies為NTCELL治療帕金森病的第三次臨牀試驗獲得資金
Oct 19 (Reuters) - Living Cell Technologies Ltd LCT.AX :
路透10月19日電-Living Cell Technologies Ltd LCT.AX：
* SECURED FUNDING FOR A THIRD CLINICAL TRIAL OF NTCELL IN PARKINSON'S DISEASE
*獲得資金，用於NTCELL在帕金森病中的第三次臨牀試驗
* COMPLETED PLACEMENT RAISING A$3.5 MILLION
*完成配售，籌集350萬澳元
Source text for Eikon: ID:nASXbgXbmM Further company coverage: LCT.AX
Eikon的源文本：ID：nASXbgXbmM進一步的公司報道：LCT.AX
((Reuters.Briefs@thomsonreuters.com;))
(Reurs.Briefs@thomsonreurs.com；)